Arine, the leader in AI-driven medication intelligence, has announced a $30 million Series C funding round led by Town Hall Ventures, with participation from Kaiser Permanente Ventures and existing investors. This latest round brings Arine's total funding to $66 million, strengthening the company's position at the forefront of healthcare innovation as it accelerates its mission to redefine medication management across the healthcare continuum.
The funding comes at a critical time when the healthcare industry faces unprecedented financial and regulatory pressures. Arine's AI platform addresses these challenges by focusing on medication optimization, delivering scalable, personalized, and cost-effective medication therapy essential for success in value-based care.
"This is a defining moment for healthcare and for Arine," said Yoona Kim, PharmD, PhD, CEO and co-founder of Arine. "Mounting cost pressures and sweeping policy changes are forcing the industry to rethink how care is delivered. Amid these challenges, medications have emerged as one of the most powerful—and underleveraged—tools to improve outcomes and control costs. With this new capital, we're expanding our ability to deliver meaningful impact for each patient, when the system needs it most."
Designed for leading health plans and risk-bearing providers, Arine's platform leverages large, diverse datasets to identify the right individuals, recommend the most effective interventions, and continuously measure impact. The company's approach has consistently achieved over 10% in total cost savings and more than 40% reduction in hospitalizations. These outcomes have driven over 100% growth in the last year and an average contract expansion of 80% with existing clients.
"The rising cost of medications and the consequences of suboptimal medication use presents significant opportunities for innovation, particularly using AI. What sets Arine apart is not just its transformative technology, but its ability to consistently deliver measurable value for clients across populations, especially in underserved communities. The company's phenomenal leadership team combines deep clinical and AI expertise with a bold vision for the future," said Andy Slavitt, General Partner at Town Hall Ventures. "Their platform is not just solving today's problems—it's anticipating tomorrow's challenges. We're proud to support Arine as they drive the next wave of healthcare innovation."
Long-term partners have validated Arine's consistent value delivery. "We've been partnering with Arine since 2020, and year after year, the value has been clear," said Caroline Carney, MD, MSc, FAPA, FAPM, CPHQ, President and Chief Medical Officer at Magellan Health. "Arine continues to expand the capabilities of their platform in ways that drive even greater impact—advancing evidence-based quality, improving patient-centered outcomes, and delivering meaningful cost savings. It's that ongoing evolution that makes them such a valuable long-term partner."
With the new funding, Arine will expand its capabilities in specialty pharmacy management, accelerate AI innovation to automate high-volume tasks, and integrate comprehensive data to further personalize medication therapy. These advancements will help set new standards for how technology can drive scalable, meaningful change in healthcare.
Click here for the original news story.